Recent studies have shown that METTL3 is upregulated and associated with poor prognosis in gastrointestinal malignancies, including liver cancer, pancreatic cancer and colorectal cancer (Li et al., 2019). This evidence concerns the gene METTL3 and familial pancreatic carcinoma.